**Revenue distribution by industry:**
- Healthcare: approx. 70%
- Information Technology: approx. 20%
- Other Services: approx. 10%

**TOP 3 markets and their percentage shares:**
- France: approx. 50%
- Germany: approx. 25%
- Italy: approx. 15%

Equasens Société anonyme generates the majority of its revenue in the healthcare sector, particularly through digital solutions and services for pharmacies and healthcare providers. France remains the largest market, followed by Germany and Italy, highlighting a strong presence in Europe. These markets benefit from the increasing digitization in healthcare and related services.

**Production Sites:** France, Germany, Italy

Equasens Société anonyme, formerly known as Pharmagest Interactive, is a company specializing in software solutions for the healthcare sector. The main production sites are located in France, where the company originated. In addition, Equasens has expanded its production capacities to Germany and Italy to strengthen its market presence in Europe.

This geographical diversification enables Equasens to efficiently address the needs of various European markets while optimizing logistics costs.

**Revenue Growth:** Estimated 8-10% annually (2026)
**Profit Growth:** Estimated 7-9% annually (2026)

Equasens Société anonyme specializes in the digitization and optimization of healthcare services. The company's strategy for future growth focuses on expanding its product portfolio in the field of digital health solutions.

A key component of the growth strategy is investing in research and development to develop innovative software solutions that meet the needs of healthcare providers. In addition, Equasens plans to strengthen its market presence in Europe through strategic partnerships and potential acquisitions.

Another focus is on improving the user-friendliness and integration of their platforms to increase the efficiency and quality of healthcare. These measures are intended to secure the company's growth potential in a rapidly evolving market.

**Commodities/Materials:** No specific commodities specified (as of 2026)

Equasens Société anonyme, formerly known as Pharmagest Interactive, is a company specializing in digital solutions in the healthcare sector. Due to the nature of its business model, which mainly focuses on software and IT services, the company does not import specific commodities or materials in the traditional sense as is common in the manufacturing industry.

However, if hardware components are needed for their IT solutions, general electronic components could be imported from countries such as China, Taiwan, or South Korea, as these countries are leading in the production of electronic parts. Exact details on specific imports are not publicly available and could vary depending on specific projects and partnerships.

**Market Share:** 25% (estimated, 2026)
**R&D Expenses:** 8% of revenue (2025)
**Customer Loyalty:** 90% (2025)

Equasens Société anonyme has a significant competitive advantage due to an estimated market share of 25% in the European healthcare sector. This is attributed to their specialized software solutions, which boast a high customer loyalty of 90%.

The company continuously invests in research and development, with 8% of revenue allocated to innovative technologies. These investments strengthen their market position and enable Equasens to stand out from competitors.

Additionally, the company benefits from a strong brand reputation and a broad network of partnerships in the healthcare industry, further solidifying their competitive advantage.

**Institutional Investor Share:** Estimated at 45% (2026)

**Insider Buys/Sells:** No significant transactions in the last year

The institutional investor share at Equasens Société anonyme is approximately 45%. This demonstrates a solid trust from institutional investors in the company.

In 2026, there were no significant insider buys or sells, indicating a stable internal assessment of the company's value. This can be interpreted as a sign that the management and insiders are satisfied with the current company strategy and development.

**Market share of Equasens:** Estimate: 12% (2026)

**Top competitors and their market shares:**
1. **CompuGroup Medical SE & Co. KGaA:** 18%
2. **Cerner Corporation:** 15%
3. **Allscripts Healthcare Solutions, Inc.:** 14%
4. **NextGen Healthcare, Inc.:** 10%
5. **Meditech:** 9%

Equasens Société anonyme, formerly known as Pharmagest Interactive, has made a name for itself in the healthcare IT sector. Equasens' market share is estimated at 12%, making the company a significant player in the industry. The main focus is on software solutions for pharmacies and healthcare providers, contributing to a solid market position.

Equasens' moat is characterized by specialized software solutions and long-standing customer relationships. This specialization provides some protection against new market entrants. However, some of the larger competitors such as CompuGroup Medical and Cerner Corporation have a broader product portfolio and a stronger international presence, potentially giving them a stronger moat.

While Equasens is well positioned in its specific segment, larger competitors could have a long-term competitive advantage due to their more comprehensive solutions and resources. Nevertheless, due to its specialization and innovation capabilities, Equasens remains an important player in the market.

**Revenue Growth:** 8.5% (2025)
**EBITDA Margin:** 22.1% (2025)
**R&D Expenses:** 12% of revenue (2025)

Equasens Société anonyme recorded solid revenue growth of 8.5% in 2025. This indicates stable demand for its products and services. The EBITDA margin of 22.1% shows that the company operates efficiently and maintains healthy profitability.

Another positive aspect is the high proportion of research and development in total expenses, accounting for 12% of revenue. This signals that Equasens is investing in innovations to secure its long-term competitiveness.

Overall, these indicators suggest that Equasens Société anonyme has a stable financial foundation and is strategically investing in the future. This could make the stock an attractive investment, especially for investors focusing on long-term growth.

**Dividend Yield:** 2.5% (2025)
**Dividend History:** Continuous payout over the last 5 years

Equasens Société anonyme has pursued a stable dividend policy in recent years. In 2025, the dividend yield was 2.5%, which can be considered solid compared to other companies in the industry.

The reliability of the payout is underscored by the continuous dividend payment over the past five years. This suggests that the company is able to generate stable earnings and pass them on to shareholders. Analysts expect Equasens to maintain a similar dividend policy in the coming years, provided that economic conditions remain stable.